[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355182-105":59,"doc-detail-355182-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pole-development-and-validation-of-a-pulmonary-embolism-prediction-model-in-lung-cancer","POLE - Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer","","Prediction models for cancer-associated pulmonary embolism (PE) in lung cancer patients remain limited. This retrospective-and-prospective study developed and validated a novel nomogram to estimate PE risk in this population and compared its discrimination with the Khorana score. The POLE model incorporated seven routinely available variables and showed good predictive accuracy in retrospective and prospective cohorts, with significant risk stratification and improved overall performance over Khorana.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pole-development-and-validation-of-a-pulmonary-embolism-prediction-model-in-lung-cancer/355182/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pole-development-and-validation-of-a-pulmonary-embolism-prediction-model-in-lung-cancer/355182.png","ImageObject",300,407,{"name":92,"@type":93},"Riley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the POLE study?","Question",{"text":112,"@type":113},"To develop and validate a novel prediction model that accurately estimates cancer-associated PE risk in lung cancer patients and to compare its performance with the Khorana score.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the POLE model developed and validated?",{"text":117,"@type":113},"A retrospective cohort (n = 476) was used to identify PE risk factors and construct the nomogram with Cox regression, and a prospective cohort (n = 140) was used for validation.",{"name":119,"@type":110,"acceptedAnswer":120},"Which variables are included in the POLE nomogram?",{"text":121,"@type":113},"The POLE model includes seven variables: activated partial thromboplastin time, D-dimer, serum phosphorus, carbohydrate antigen 19-9, history of lung cancer surgery, targeted therapy, and age.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355182,1790970118,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","POLE: Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer  \nClinical and Applied Thrombosis/Hemostasis Volume 32: 1-11 © The Author(s) 2026 Article reuse guidelines:  \n[sagepub.com/journals-permissions](sagepub.com/journals-permissions)[ ](sagepub.com/journals-permissions)[DOI: 10.1177/10760296261428826](DOI: 10.1177/10760296261428826)[ ](DOI: 10.1177/10760296261428826)[journals.sagepub.com/home/cat](journals.sagepub.com/home/cat)  \nDongmei Wang, MS 1 , Wei Xiong, MD, PhD 1,2 , Xuan Huang, MS 1  , Fan Zhang, MS 1 , Fengming Xu, MS 1 , and Fengfeng Han, MS 1   \nAbstract  \nBackground: Prediction models for cancer-associated pulmonary embolism (PE) in lung cancer patients are scarce. This study aimed to develop and validate a novel model to accurately predict PE risk in this population.  \nMethods: A retrospective cohort (n = 476) was used to identify PE-related risk factors and construct a predictive nomogram using Cox regression. Validation was performed in a prospective cohort (n = 140). The model’s performance was compared with the Khorana score.  \nResults: The newly developed nomogram termed Pulmonary embOlism in Lung cancEr ( POLE) included seven variables: activated partial thromboplastin time, D-dimer, serum phosphorus, carbohydrate antigen 19-9, history of lung cancer surgery, targeted therapy, and age. It demonstrated good predictive performance in the retrospective study (area under the curve [AUC]: 0.776, 95% conﬁdence interval [CI] 0.720-0.833, P\u003C0.001). The AUC values at 1, 3, 6, and 9 months after lung cancer diagnosis were 0.840, 0.839, 0.799, and 0.801, respectively. In the prospective study, the AUC values for the POLE model at 1, 3, 6, and 9 months after lung cancer diagnosis were 0.859, 0.806, 0.754, and 0.746, respectively. Moreover, in both derivation and validation cohorts, there were signiﬁcant differences in the probability of PE occurrence among lung cancer patients being stratiﬁed into different risk strata (all P\u003C0.001). The POLE model (AUC 0.762) outperformed the Khorana score (AUC 0.560).  \nConclusions: The POLE model, based on seven clinical parameters, was developed and validated for predicting cancer-associated PE in lung cancer patients, demonstrating high accuracy, calibration, and stability.  \nKeywords  \nlung cancer, pulmonary embolism, risk factor, risk assessment, prediction model  \nReceived: 9 October 2025; accepted: 9 December 2025  \nIntroduction  \nCancer-associated venous thromboembolism (VTE) is the second leading cause of death in cancer patients.1 Lung cancer, one of the most common malignancies worldwide,2 carries a particularly high risk of VTE.3  \nPulmonary embolism (PE), a potentially lifethreatening form of VTE, was found4 in 12 .4% of deceased cancer patients, with PE-related deaths accounting for 6.7% of the total population. Among patients with autopsy-conﬁrmed PE, lung cancer patients represented the largest proportion (27 .2%) . A meta-analysis5 reported that the overall incidence of PE in lung cancer was 3.7%,  \nranging from 1.3% to 23.7% . First-time PE in lung cancer patients often signals severe disease and poor prognosis,6 highlighting the need for early risk prediction.  \n1 Department of Respiratory Medicine, Xin Hua Hospital Afﬁliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China 2Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan  \nCorresponding Author:  \nFengfeng Han, No. 1665, Kongjiang Road, Yangpu District, Shanghai, 200092, China.  \nEmail: [hanfengfeng@xinhuamed.com.cn](hanfengfeng@xinhuamed.com.cn)  \nCreative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)) which permits non-commercial use,  \nreproduction and distribution of the work without further permission provided the ori","cbCaimN6sMWerZ6t","https://ap.wps.com/l/cbCaimN6sMWerZ6t","pdf",1802880,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods\n## Study Design\n## Study Population","[{\"question\":\"What was the main goal of the POLE study?\",\"answer\":\"To develop and validate a novel prediction model that accurately estimates cancer-associated PE risk in lung cancer patients and to compare its performance with the Khorana score.\"},{\"question\":\"How was the POLE model developed and validated?\",\"answer\":\"A retrospective cohort (n = 476) was used to identify PE risk factors and construct the nomogram with Cox regression, and a prospective cohort (n = 140) was used for validation.\"},{\"question\":\"Which variables are included in the POLE nomogram?\",\"answer\":\"The POLE model includes seven variables: activated partial thromboplastin time, D-dimer, serum phosphorus, carbohydrate antigen 19-9, history of lung cancer surgery, targeted therapy, and age.\"}]","POLE - Development and Validation of a Pulmonary Embolism Prediction Model in Lung Cancer | PDF",1790116553,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63b325d765cf4e2b0a42e274871edc6e.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f8e04e9dcd6c23f38e0a3dd156a9cd9c.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b2a74a6a4aec32890b0cb503f89eddc.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3721b58698b96e0d6ec4a196cacea10.webp",980,1311]